What Analyst Projections for Key Metrics Reveal About Regeneron (REGN) Q1 Earnings

Core Viewpoint - Analysts expect Regeneron to report quarterly earnings of $8.76 per share, reflecting a year-over-year decline of 8.3%, with revenues projected at $3.25 billion, an increase of 3.3% from the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised 6.1% lower in the last 30 days, indicating a collective reevaluation by analysts [1][2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [2]. Revenue Projections - Analysts predict 'Revenues- Other Revenue' to reach $132.13 million, a 13% increase year-over-year [4]. - 'Revenues- Net product sales' are expected to be $1.62 billion, indicating a decline of 8.2% from the previous year [4]. - 'Total Bayer collaboration revenue' is projected at $374.73 million, reflecting a 5.3% year-over-year increase [4]. - The consensus estimate for 'Revenues- Collaboration' stands at $1.49 billion, a 17.9% increase from the year-ago quarter [5]. Product-Specific Revenue Estimates - 'Revenues- Praluent (alirocumab)- US' are expected to be $57.71 million, down 17.6% year-over-year [5]. - 'Revenues- Eylea (Aflibercept)- US' are projected at $1.19 billion, indicating a decline of 15.2% [5]. - 'Revenues- Evkeeza- US' are estimated at $32.40 million, a 35% increase year-over-year [6]. - 'Revenues- Libtayo- ROW' are expected to reach $127.95 million, reflecting a 22.2% increase [6]. - 'Revenues- Libtayo- US' are projected at $214.99 million, indicating a 35% year-over-year increase [6]. - 'Revenues- Dupixent (dupilumab)- ROW' are expected to be $1.08 billion, a 25.7% increase [7]. - 'Revenues- Kevzara (sarilumab)- ROW' are projected at $41.91 million, down 5% year-over-year [7]. - 'Revenues- Kevzara (sarilumab)- US' are expected to reach $52.50 million, indicating a 5% increase [7]. Stock Performance - Over the past month, Regeneron shares have declined by 8.2%, compared to a 5.1% decline in the Zacks S&P 500 composite [8]. - Based on its Zacks Rank 4 (Sell), Regeneron is expected to underperform the overall market in the upcoming period [8].